Zimmer Biomet/$ZBH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zimmer Biomet
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Ticker
$ZBH
Sector
Primary listing
NYSE
Employees
17,000
Headquarters
Website
Zimmer Biomet Metrics
BasicAdvanced
$18B
21.94
$4.03
0.61
$0.96
1.08%
Price and volume
Market cap
$18B
Beta
0.61
52-week high
$114.44
52-week low
$85.33
Average daily volume
1.8M
Dividend rate
$0.96
Financial strength
Current ratio
2.428
Quick ratio
1.203
Long term debt to equity
58.849
Total debt to equity
63.548
Dividend payout ratio (TTM)
23.69%
Interest coverage (TTM)
5.53%
Profitability
EBITDA (TTM)
2,637.6
Gross margin (TTM)
71.46%
Net profit margin (TTM)
10.05%
Operating margin (TTM)
19.56%
Effective tax rate (TTM)
20.99%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
4.32%
Return on equity (TTM)
6.42%
Valuation
Price to earnings (TTM)
21.944
Price to revenue (TTM)
2.193
Price to book
1.37
Price to tangible book (TTM)
-10.47
Price to free cash flow (TTM)
15.536
Free cash flow yield (TTM)
6.44%
Free cash flow per share (TTM)
5.697
Dividend yield (TTM)
1.08%
Forward dividend yield
1.08%
Growth
Revenue change (TTM)
5.47%
Earnings per share change (TTM)
-23.28%
3-year revenue growth (CAGR)
5.14%
10-year revenue growth (CAGR)
4.24%
3-year earnings per share growth (CAGR)
44.83%
10-year earnings per share growth (CAGR)
15.36%
10-year dividend per share growth (CAGR)
0.87%
What the Analysts think about Zimmer Biomet
Analyst ratings (Buy, Hold, Sell) for Zimmer Biomet stock.
Bulls say / Bears say
Zimmer Biomet raised its 2025 adjusted EPS guidance to $8.10–$8.30 and reduced its projected tariff headwind to $40 million from $60–$80 million after Q2 results exceeded estimates, reflecting effective cost controls and strong device demand (Reuters).
In Q3 2025, Zimmer reported adjusted EPS of $1.90 and net sales up 9.7% to $2.00 billion, driven by strength in hips and knees and a 19% increase in sports medicine and trauma products (Reuters).
Zimmer’s July 2025 deal to acquire Monogram Technologies for $177 million expands its ROSA robotics platform with FDA-cleared, semi-autonomous knee surgery technology, positioning the company to lead in fully autonomous surgical robotics (Reuters).
On November 5, 2025, Zimmer cut its 2025 organic revenue growth guidance to 3.5%–4.0% from 3.5%–4.5% after reporting weaker-than-expected results in Latin America and emerging Europe, causing shares to fall 15% (Reuters).
The company's third-quarter organic sales growth of 5.0% was below analyst expectations of 5.6%, highlighting a slowdown as competition intensifies outside the U.S. (Reuters).
Zimmer expects the Monogram acquisition to be neutral to adjusted EPS through 2027 before becoming accretive, suggesting short-term dilution and integration risks (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.
Zimmer Biomet Financial Performance
Revenues and expenses
Zimmer Biomet Earnings Performance
Company profitability
Zimmer Biomet News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zimmer Biomet stock?
Zimmer Biomet (ZBH) has a market cap of $18B as of November 09, 2025.
What is the P/E ratio for Zimmer Biomet stock?
The price to earnings (P/E) ratio for Zimmer Biomet (ZBH) stock is 21.94 as of November 09, 2025.
Does Zimmer Biomet stock pay dividends?
Yes, the Zimmer Biomet (ZBH) stock pays dividends to shareholders. As of November 09, 2025, the dividend rate is $0.96 and the yield is 1.08%. Zimmer Biomet has a payout ratio of 23.69% on a trailing twelve-month basis.
When is the next Zimmer Biomet dividend payment date?
The next Zimmer Biomet (ZBH) dividend payment date is unconfirmed.
What is the beta indicator for Zimmer Biomet?
Zimmer Biomet (ZBH) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.